Vysis® UroVysion for the detection of urothelial carcinoma

Expert Review of Molecular Diagnostics

Volumn 3, Issue 4, 2003, Pages 507-519

  Halling, Kevin C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Bladder cancer; Bladder tumor markers; FISH; Urine cytology; Urothelial carcinoma; Vysis UroVysion

Indexed keywords

ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER RECURRENCE; CYSTECTOMY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERMETHOD COMPARISON; NEPHROURETERECTOMY; REVIEW; SENSITIVITY AND SPECIFICITY; URINE CYTOLOGY; UROGENITAL TRACT CANCER; ARTICLE; BLADDER TUMOR; CANCER STAGING; CARCINOMA; CYTOLOGY; GENETICS; METHODOLOGY; PATHOLOGY; PROSPECTIVE STUDY; URINE; UROTHELIUM;

CARCINOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM STAGING; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; URINARY BLADDER NEOPLASMS; URINE; UROTHELIUM;

EID: 0037484597     PISSN: 14737159     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.3.4.507     Document Type: Review

References (63)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin. 53(1), 5-26 (2003).
2. McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am. J. Surg. Pathol. 25(3), 356-362 (2001).
3. Droller MJ. Bladder cancer: state-of-the-art care. CA Cancer J. Clin. 48(5), 269-284 (1998).
4. Dubernard JM, Devonec M, Amid J, Bouvier R, Fontaniere B, Faucon M. Correlation between cytology and cystoscopy in the follow-up of patients with bladder tumours. Eur. Urol. 8(1), 5-8 (1982).
5. Farrow GM. Urine cytology in the detection of bladder cancer: a critical approach. J. Occup. Med. 32(9), 817-821 (1990).
6. Halling KC, King W, Sokolova IA et al. A comparison of cytology and fluorescence in situ hybridization for the detection of bladder cancer. J. Urol. 164, 1768-1775 (2000). Initial study demonstrating that fluorescence in situ hybridization (FISH) with UroVysion is significantly more sensitive but just as specific as urine cytology for the detection of urothelial carcinoma.
7. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PMM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer: a systematic review. J. Urol. 169, 198-220 (2003).
8. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J. Urol. 165(2), 600-611 (2001).
9. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity. J. Urol. 165, 1067-1077 (2001).
10. Mao L, Schoenberg MP, Scicchitano M et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science 271(5249), 659-662 (1996).
11. Cajulis RS, Haines GK, Frias-Hidvegi D, McVary K, Bacus JW. Cytology, flow cytometry, image analysis and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diag. Cytopathol. 13(3), 214-223 (1995).
12. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54(3), 784-788 (1994). First to suggest that there may be two molecular genetic pathways leading to the formation of urothelial carcinoma.
13. Cairns P, Shaw ME, Knowles MA. Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. Oncogene 8(4), 1083-1085 (1993).
14. Richter J, Jiang F, Gorog JP et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res. 57(14), 2860-2864 (1997). Demonstrated that there are marked differences in the chromosomal abnormalities present between pTa and pT1 tumors and these differences likely explain the differences in the biological behavior of these two types of tumors.
15. Kallioniemi A, Kallioniemi OP, Citro G et al. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chrom. Cancer 12(3), 213-219 (1995).
16. Hovey RM, Chu L, Balazs M et al. Genetic alterations in primary bladder cancers and their metastases. Cancer Res. 58(16), 3555-3560 (1998).
17. Voorter C, Joos S, Bringuier PP et al. Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. Am. J. Pathol. 146(6), 1341-1354 (1995).
18. Dalquen P, Kleiber B, Grilli B, Herzog M, Bubendorf L, Oberholzer M. DNA image cytometry and fluorescence in situ hybridization for noninvasive detection of urothelial tumors in voided urine. Cancer Cytopathol. 96, 374-379 (2002).
19. al-Abadi H, Nagel R. Deoxyribonucleic acid content and survival rates of patients with transitional cell carcinoma of the bladder. J. Urol. 151 (1), 37-42 (1994).
20. Hug EB, Donnelly SM, Shipley WU et al. Deoxyribonucleic acid flow cytometry in invasive bladder carcinoma: a possible predictor for successful bladder preservation following transurethral surgery and chemotherapy-radiotherapy. J. Urol. 148(1), 47-51 (1992).
21. Slaton JW, Dinney CP, Veltri RW et al. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. Urol. 158(3 Pt 1), 806-811 (1997).
22. Bittard H, Lamy B, Billery C. Clinical evaluation of cell deoxyribonucleic acid content measured by flow cytometry in bladder cancer. J. Urol. 155, 1887-1891 (1996).
23. Wheeless LL, Reeder JE, Han R et al. Bladder irrigation specimens assayed by fluorescence in situ hybridization to interphase nuclei. Cytometry 17(4), 319-326 (1994).
24. Junker K, Werner W, Mueller C, Ebert W, Schubert J, Claussen U. Interphase cytogenetic diagnosis of bladder cancer on cells from urine and bladder washing. Int. J. Oncol. 14(2), 309-313 (1999).
25. Pycha A, Mian C, Haitel A, Hofbauer J, Wiener H, Marberger M. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. J. Urol. 157(6), 2116-2119 (1997).
26. Pycha A, Mian C, Posch B et al. Numerical aberrations of chromosomes 7, 9 and 17 in squamous cell and transitional cell cancer of the bladder: a comparative study performed by fluorescence in situ hybridization. J. Urol. 160, 737-740 (1998).
27. Pycha A, Mian C, Hofbauer J, Haitel A, Wiener H, Marberger M. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer? J. Urol. 159(1), 265-269 (1998).
28. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Med 3(6), 621-624 (1997).
29. Olumi AF, Tsai YC, Nichols PW et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res. 50(21), 7081-7083 (1990).
30. Presti JCJ, Reuter VE, Galan T, Fair WR, Cordon-Cardo C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res. 51(19), 5405-5409 (1991).
31. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 342(8869), 469-471 (1993).
32. Brewster SF, Gingell JC, Browne S, Brown KW. Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell carcinoma of the bladder. Br. J. Cancer 70(4), 697-700 (1994).
33. Chang WY, Cairns P, Schoenberg MP, Polascik TJ, Sidransky D. Novel suppressor loci on chromosome 14q in primary bladder cancer. Cancer Res. 55(15), 3246-3249 (1995).
34. Simoneau AR, Spruck CH, Gonzalez-Zulueta M et al. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations. Cancer Res. 56(21), 5039-5043 (1996).
35. Habuchi T, Ogawa O, Kakehi Y et al. Accumulated allelic losses in the development of invasive urothelial cancer. Int. J. Cancer 53(4), 579-584 (1993).
36. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res. 54(2), 531-538 (1994).
37. Rosin MP, Cairns P, Epstein JI, Schoenberg MP, Sidransky D. Partial allelotype of carcinoma in situ of the human bladder. Cancer Res. 55(22), 5213-5216 (1995).
38. Gonzalez-Zulueta M, Ruppert JM, Tokino K et al. Microsatellite instability in bladder cancer. Cancer Res. 53(23), 5620-5623 (1993).
39. Hartmann A, Zanardo L, Bocker-Edmonston T et al. Frequent microsatellite instability in sporadic tumors of the upper urinary tract. Cancer Res. 62(23), 6796-6802 (2002).
40. Ruppert JM, Tokino K, Sidransky D. Evidence for two bladder cancer suppressor loci on human chromosome 9. Cancer Res. 53(21), 5093-5095 (1993).
41. Balazs M, Carroll P, Kerschmann R, Sauter G, Waldman FM. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chrom. Cancer 19(2), 84-89 (1997).
42. Orlow I, Lacombe L, Hannon GJ et al. Deletion of the p16 and p15 genes in human bladder tumors. J. Natl Cancer Inst. 87(20), 1524-1529 (1995).
43. Esrig D, Spruck CH, Nichols PW et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade and stage in bladder cancer. Am. J. Pathol. 143(5), 1389-1397 (1993).
44. Fujimoto K, Yamada Y, Okajima E et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res. 52(6), 1393-1398 (1992).
45. Matsuyama H, Pan Y, Mahdy EA et al. p53 deletion as a genetic marker in urothelial tumor by fluorescence in situ hybridization. Cancer Res. 54(23), 6057-6060 (1994).
46. Tsutsumi M, Sugano K, Yamaguchi K, Kakizoe T, Akaza H. Correlation of allelic loss of the p53 gene and tumor grade, stage and malignant progression in bladder cancer. Int. J. Urol. 4(1), 74-78 (1997).
47. Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM, Schalken JA. p53 mutations have no additional prognostic value over stage in bladder cancer. Br. J. Cancer 70(3), 496-500 (1994).
48. Sauter G, Mihatsch MJ. Pussycats and baby tigers: noninvasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same. J. Pathol. 185(4), 339-341 (1998).
49. Jallepalli PV, Lengauer C. Chromosome segregation and cancer: cutting through the mystery. Nature Rev. Cancer 1, 109-117 (2001).
50. Sokolova IA, Halling KC, Jenkins RB et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J. Mol. Diagn. 2, 116-123 (2000). Describes the development and validation of the UroVysion probe set.
51. Halling KC, King W, Sokolova IA et al. A comparison of BTA-stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J. Urol. 167(5), 2001-2006 (2002). Study of the relative sensitivity and specificity of UroVysion, BTA-stat, telomerase and hemoglobin dipstick analysis that reveals that UroVysion has the highest combined sensitivity and specificity (i.e., highest diagnostic accuracy) of the four assays tested.
52. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J. Urol. 153(3 Pt 1), 564-572 (1995).
53. Farrow GM. Pathology of carcinoma in situ of the urinary bladder and related lesions. J. Cell. Biochem. Suppl. 161, 39-43 (1992).
54. Zincke H, Utz DC, Farrow GM. Review of Mayo Clinic experience with carcinoma in situ. Urology 26(4 Suppl.), 39-46 (1985).
55. Koss LG. Bladder cancer from a perspective of 40 years. J. Cell. Biochem. Suppl. 16I, 23-29 (1992).
56. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am. J. Clin. Pathol. 116(1), 79-86 (2001). Demonstrates that UroVysion is more sensitive and just as specific as urine cytology.
57. Skacel M, Pettay JD, Tsiftsakis EK, Procop GW, Biscotti CV, Tubbs RR. Validation of a multicolor interphase fluorescence in situ hybridization assay for detection of transitional cell carcinoma on fresh and archival thin-layer, liquid-based cytology slides. Anal. Quant. Cytol. Histol. 23(6), 381-387 (2001). UroVysion is performed on archival thin-layer, liquid-based cytology slides. The study reveals that the cells that are abnormal by conventional cytology are also the same cells that exhibit chromosomal abnormalities with UroVysion.
58. Skacel M, Fahmy M, Brainard JA et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J. Urol. 169, 2101-2105 (2003). Among patients with biopsy-proven urothelial carcinoma who had a negative cytology result, 60% were positive for abnormality with UroVysion.
59. Sarosdy MF, Schellhammer P, Bokinsky G et al. Clinical evaluation of a multitarget fluorescent in situ hybridization assay for detection of bladder cancer. J. Urol. 168(5), 1950-1954 (2002). Description of the study that led to FDA approval of UroVysion. Also demonstrates the clinical significance of 'anticipatory positive' UroVysion results.
60. Kriegmair M, Zaak D, Rothenberger KH et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J. Urol. 168(2), 475-478 (2002).
61. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J. Urol. 168 (1), 67-71 (2002).
62. Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J. Urol. 165(4), 1121-1123 (2001).
63. Karnes RJ, Lieber M, Zincke H, Blute ML, Halling KC. Can urine fluoresence in situ hybridization (FISH) predict Bacillus Calmette-Guerin (BCG) failures? AUA Meeting, North Central Section, 2002. (Abstract)